Ophthalmology Perspectives | Ep 3 | Gene Therapy, Patient-Centric Operations, and Risk-Benefit Challenges in Phase 1 Ophthalmology Trials

Today we explore the unique challenges and opportunities in Phase 1 ophthalmology clinical trials, focusing on gene therapy and inherited retinal diseases. Host: Amber BurgParticipants: David Hoelscher, Senior Medical Director, Ophthalmology Tanya Richardson, Therapeutic Strategy Head, Ophthalmology and Neuroscience

Episode metadata supplied by the publisher feed · Published Feb 4, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Ophthalmology Perspectives | Ep 3 | Gene Therapy, Patient-Centric Operations, and Risk-Benefit Challenges in Phase 1 Ophthalmology Trials

0:00 30:45

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Fortrea Podcast?

This episode is 30 minutes long.

When was this The Fortrea Podcast episode published?

This episode was published on February 4, 2026.

Can I download this The Fortrea Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!